These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 33703978)

  • 1. Osilodrostat for the treatment of Cushing's disease.
    Rasool S; Skinner BW
    Expert Opin Pharmacother; 2021 Jun; 22(9):1099-1106. PubMed ID: 33703978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
    Pivonello R; Fleseriu M; Newell-Price J; Bertagna X; Findling J; Shimatsu A; Gu F; Auchus R; Leelawattana R; Lee EJ; Kim JH; Lacroix A; Laplanche A; O'Connell P; Tauchmanova L; Pedroncelli AM; Biller BMK;
    Lancet Diabetes Endocrinol; 2020 Sep; 8(9):748-761. PubMed ID: 32730798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osilodrostat oral tablets for adults with Cushing's disease.
    Martino M; Aboud N; Lucchetti B; Salvio G; Arnaldi G
    Expert Rev Endocrinol Metab; 2022 Mar; 17(2):99-109. PubMed ID: 35220871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease.
    Fleseriu M; Pivonello R; Young J; Hamrahian AH; Molitch ME; Shimizu C; Tanaka T; Shimatsu A; White T; Hilliard A; Tian C; Sauter N; Biller BM; Bertagna X
    Pituitary; 2016 Apr; 19(2):138-48. PubMed ID: 26542280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corticotroph tumor progression during long-term therapy with osilodrostat in a patient with persistent Cushing's disease.
    Fontaine-Sylvestre C; Létourneau-Guillon L; Moumdjian RA; Berthelet F; Lacroix A
    Pituitary; 2021 Apr; 24(2):207-215. PubMed ID: 33074401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Utility of Osilodrostat in Cushing's Disease: Review of Currently Available Literature.
    Perosevic M; Tritos NA
    Drug Des Devel Ther; 2023; 17():1303-1312. PubMed ID: 37143705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osilodrostat: A Novel Steroidogenesis Inhibitor to Treat Cushing's Disease.
    Dougherty JA; Desai DS; Herrera JB
    Ann Pharmacother; 2021 Aug; 55(8):1050-1060. PubMed ID: 33143437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osilodrostat - an emerging drug for the medical management of Cushing's disease.
    Witek P; Mehlich A; Stasiewicz A; Jawiarczyk-Przybyłowska A; Bolanowski M
    Endokrynol Pol; 2022; 73(2):371-374. PubMed ID: 35381096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11β-hydroxylase inhibitor, in Japanese patients with endogenous Cushing's syndrome other than Cushing's disease.
    Tanaka T; Satoh F; Ujihara M; Midorikawa S; Kaneko T; Takeda T; Suzuki A; Sato M; Shimatsu A
    Endocr J; 2020 Aug; 67(8):841-852. PubMed ID: 32378529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy and safety of osilodrostat in patients with Cushing's disease: results from the LINC 4 study extension.
    Gadelha M; Snyder PJ; Witek P; Bex M; Belaya Z; Turcu AF; Feelders RA; Heaney AP; Paul M; Pedroncelli AM; Auchus RJ
    Front Endocrinol (Lausanne); 2023; 14():1236465. PubMed ID: 37680892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Cushing's syndrome with osilodrostat: practical applications of recent studies with case examples.
    Fleseriu M; Biller BMK
    Pituitary; 2022 Dec; 25(6):795-809. PubMed ID: 36002784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy and safety of osilodrostat in Cushing's disease: final results from a Phase II study with an optional extension phase (LINC 2).
    Fleseriu M; Biller BMK; Bertherat J; Young J; Hatipoglu B; Arnaldi G; O'Connell P; Izquierdo M; Pedroncelli AM; Pivonello R
    Pituitary; 2022 Dec; 25(6):959-970. PubMed ID: 36219274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study.
    Bertagna X; Pivonello R; Fleseriu M; Zhang Y; Robinson P; Taylor A; Watson CE; Maldonado M; Hamrahian AH; Boscaro M; Biller BM
    J Clin Endocrinol Metab; 2014 Apr; 99(4):1375-83. PubMed ID: 24423285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcomes of osilodrostat in Cushing's disease: LINC 3 study extension.
    Fleseriu M; Newell-Price J; Pivonello R; Shimatsu A; Auchus RJ; Scaroni C; Belaya Z; Feelders RA; Vila G; Houde G; Walia R; Izquierdo M; Roughton M; Pedroncelli AM; Biller BMK
    Eur J Endocrinol; 2022 Oct; 187(4):531-541. PubMed ID: 35980235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osilodrostat: 11β-hydroxylase inhibitor for treatment of Cushing's disease.
    Paton DP
    Drugs Today (Barc); 2020 Oct; 56(10):643-654. PubMed ID: 33185629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Updates in adrenal steroidogenesis inhibitors for Cushing's syndrome - A practical guide.
    Varlamov EV; Han AJ; Fleseriu M
    Best Pract Res Clin Endocrinol Metab; 2021 Jan; 35(1):101490. PubMed ID: 33707082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osilodrostat in Cushing's disease: the management of its efficacy and the pitfalls of post-surgical results.
    Antonini S; Brunetti A; Zampetti B; Boeris D; Saladino A; Cesare Cozzi R
    Endocrinol Diabetes Metab Case Rep; 2022 Nov; 2022():. PubMed ID: 36515363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osilodrostat: A Review of Recent Clinical Studies and Practical Recommendations for its Use in the Treatment of Cushing Disease.
    Yuen KCJ
    Endocr Pract; 2021 Sep; 27(9):956-965. PubMed ID: 34389514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of bilateral adrenalectomy in the treatment of refractory Cushing's disease.
    Wong A; Eloy JA; Liu JK
    Neurosurg Focus; 2015 Feb; 38(2):E9. PubMed ID: 25639327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discontinuation of Drug Treatment in Cushing's Disease Not Cured by Pituitary Surgery.
    Ghalawinji A; Drezet L; Chaffanjon P; Muller M; Sturm N; Simiand A; Lazard A; Gay E; Chabre O; Cristante J
    J Clin Endocrinol Metab; 2024 Mar; 109(4):1000-1011. PubMed ID: 37962981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.